

DAFTAR PUSTAKA

- Abd Elhamid, A. H., Mohamed, A. a. E. A. & Khattab, A. M. 2020. Intravitreal Aflibercept injection with Panretinal photocoagulation versus early Vitrectomy for diabetic vitreous hemorrhage: randomized clinical trial. *BMC Ophthalmol.*, 20, 1-9.
- Afarid, M., Sarvestani, A. S., Rahat, F. & Azimi, A. 2018. Intravitreal injection of bevacizumab: review of our previous experience. *Iran. J. Pharm. Res.*, 17, 1093.
- Alagöz, C., Yıldırım, Y., Kocamaz, M., Baz, Ö., Çiçek, U., Çelik, B., Demirkale, H. İ., Yazıcı, A. T. & Taşkapılı, M. 2016. The efficacy of intravitreal bevacizumab in vitreous hemorrhage of diabetic subjects. *Turkish journal of ophthalmology*, 46, 221.
- Antoszyk, A. N., Glassman, A. R., Beaulieu, W. T., Jampol, L. M., Jhaveri, C. D., Punjabi, O. S., Salehi-Had, H., Wells, J. A., Maguire, M. G. & Stockdale, C. R. 2020. Effect of intravitreal aflibercept vs vitrectomy with panretinal photocoagulation on visual acuity in patients with vitreous hemorrhage from proliferative diabetic retinopathy: a randomized clinical trial. *JAMA*, 324, 2383-2395.
- Bandello, F., Zarbin, M. A., Lattanzio, R. & Zucchiatti, I. 2016. *Clinical Strategies in the Management of Diabetic Retinopathy*, Springer.
- Chakrabarti, R., Harper, C. A. & Keeffe, J. E. 2012. Diabetic retinopathy management guidelines. *Expert Rev. Ophthalmol.*, 7, 417-439.
- Chelala, E., Nehme, J., El Rami, H., Aoun, R., Dirani, A., Fadlallah, A. & Jalkh, A. 2018. Efficacy of intravitreal ranibizumab injections in the treatment of vitreous hemorrhage related to proliferative diabetic retinopathy. *Retina*, 38, 1127-1133.
- De Nie, K. F., Crama, N., Tilanus, M. A., Klevering, B. J. & Boon, C. J. 2013. Pars plana vitrectomy for disturbing primary vitreous floaters: clinical outcome and patient satisfaction. *Graefes' Archive for Clinical and Experimental Ophthalmology*, 251, 1373-1382.
- El Annan, J. & Carvounis, P. E. 2014. Current management of vitreous hemorrhage due to proliferative diabetic retinopathy. *Int. Ophthalmol. Clin.*, 54, 141.
- Fasih, U., Shaikh, N., Rahman, A., Sultan, S., Fehmi, M. S. & Shaikh, A. 2013. A one-year follow-up study of ocular and systemic complications of intravitreal injection of bevacizumab (Avastin). *JPMA*, 63.
- Fassbender, J. M., Ozkok, A., Canter, H. & Schaal, S. 2015. A comparison of early and delayed vitrectomy for management of vitreous hemorrhage due to proliferative diabetic retinopathy. *Invest. Ophthalmol. Vis. Sci.*, 56, 5117-5117.
- Fassbender, J. M., Ozkok, A., Canter, H. & Schaal, S. 2016. A comparison of immediate and delayed vitrectomy for the management of vitreous hemorrhage due to proliferative diabetic retinopathy. *Ophthalmic. Surg. Lasers Imaging*, 47, 35-41.
- Glassman, A. R., Beaulieu, W. T., Maguire, M. G., Antoszyk, A. N., Chow, C. C., Elman, M. J., Jampol, L. M., Salehi-Had, H., Sun, J. K. & Network, D. R. 2021. Visual acuity, vitreous hemorrhage, and other ocular outcomes after vitrectomy vs aflibercept for vitreous hemorrhage due to diabetic

- retinopathy: a secondary analysis of a randomized clinical trial. *JAMA Ophthalmol.*, 139, 725-733.
- Jorge, D. M., Neto, J. E. D. S. T., Poli-Neto, O. B., Scott, I. U. & Jorge, R. 2021. Intravitreal bevacizumab (IVB) versus IVB in combination with pars plana vitrectomy for vitreous hemorrhage secondary to proliferative diabetic retinopathy: a randomized clinical trial. *International Journal of Retina and Vitreous*, 7, 1-9.
- Kang, Q. & Yang, C. 2020. Oxidative stress and diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications. *Redox Biology*, 101799.
- Kleinberg, T. T., Tzekov, R. T., Stein, L., Ravi, N. & Kaushal, S. 2011. Vitreous substitutes: a comprehensive review. *Surv. Ophthalmol.*, 56, 300-323.
- Kokavec, J., Min, S. H., Tan, M. H., Gilhotra, J. S., Newland, H. S., Durkin, S. R., Grigg, J. & Casson, R. J. 2016. Biochemical analysis of the living human vitreous. *Clinical & experimental ophthalmology*, 44, 597-609.
- Lieberman Ronni, M., Gow, J. & Grillone, L. 2006. Development and Implementation of a Vitreous Hemorrhage Grading Scale. *Retinal Physician, Issue: May*.
- Lois, N., Mccarter, R. V., O'neill, C., Medina, R. J. & Stitt, A. W. 2014. Endothelial progenitor cells in diabetic retinopathy. *Front. Endocrinol. (Lausanne)*, 5, 44.
- Mansour, S. E., Browning, D. J., Wong, K., Flynn Jr, H. W. & Bhavsar, A. R. 2020. The evolving treatment of diabetic retinopathy. *Clinical Ophthalmology (Auckland, NZ)*, 14, 653.
- Mbagwu, M., French, D. D., Gill, M., Mitchell, C., Jackson, K., Kho, A. & Bryar, P. J. 2016. Creation of an accurate algorithm to detect snellen best documented visual acuity from ophthalmology electronic health record notes. *JMIR medical informatics*, 4, e14.
- Network, D. R. C. R. 2013. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. *JAMA Ophthalmol.*, 131, 283-293.
- Omari, A. & Mahmoud, T. H. 2020. Vitrectomy. *StatPearls [Internet]*.
- Osaadon, P., Fagan, X., Lifshitz, T. & Levy, J. 2014. A review of anti-VEGF agents for proliferative diabetic retinopathy. *Eye*, 28, 510-520.
- Qazi, H. A. 2012. Protocol: Effect of intravitreal bevacizumab (avastin) in the treatment of macular edema: A systematic review of randomized controlled trials. *Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences*, 17, 1180.
- Ratnarajan, G., Mellington, F., Saldanha, M., De Silva, S. & Benjamin, L. 2011. Long-term visual and retinopathy outcomes in a predominately type 2 diabetic patient population undergoing early vitrectomy and endolaser for severe vitreous haemorrhage. *Eye*, 25, 704-709.
- Rush, R. B., Velazquez, J. C., Rosales, C. R. & Rush, S. W. 2022. Gas Tamponade for the Prevention of Postoperative Vitreous Hemorrhaging After Diabetic Vitrectomy: A Randomized Clinical Trial. *Am. J. Ophthalmol.*, 242, 173-180.
- Sampat, K. M. & Garg, S. J. 2010. Complications of intravitreal injections. *Current opinion in ophthalmology*, 21, 178-183.

- Sasongko, M. B., Widyaputri, F., Agni, A. N., Wardhana, F. S., Kotha, S., Gupta, P., Widayanti, T. W., Haryanto, S., Widyaningrum, R. & Wong, T. Y. 2017. Prevalence of diabetic retinopathy and blindness in Indonesian adults with type 2 diabetes. *Am. J. Ophthalmol.*, 181, 79-87.
- Schulz-Key, S., Carlsson, J. O. & Crafoord, S. 2011. Longterm follow-up of pars plana vitrectomy for vitreous floaters: complications, outcomes and patient satisfaction. *Acta Ophthalmol. (Copenh.)*, 89, 159-165.
- Scott, I. U., Smiddy, W. E., Feuer, W. & Merikansky, A. 1998. Vitreoretinal surgery outcomes: results of a patient satisfaction/functional status survey. *Ophthalmology*, 105, 795-803.
- Seah, I., Zhao, X., Lin, Q., Liu, Z., Su, S. Z. Z., Yuen, Y. S., Hunziker, W., Lingam, G., Loh, X. J. & Su, X. 2020. Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases. *Eye*, 34, 1341-1356.
- Siegel, N. H., Fiorello, M. G., Ness, S., Kim, J., Vig, V., Peeler, C. E., Chen, X. & Subramanian, M. L. 2021. Patient Satisfaction With Oral vs Intravenous Sedation for Vitrectomy Surgery: A Randomized, Noninferiority Clinical Trial. *Journal of VitreoRetinal Diseases*, 24741264211027820.
- Steinberg, E. P., Tielsch, J. M., Schein, O. D., Javitt, J. C., Sharkey, P., Cassard, S. D., Legro, M. W., Diener-West, M., Bass, E. B. & Damiano, A. M. 1994. The VF-14: an index of functional impairment in patients with cataract. *Arch. Ophthalmol.*, 112, 630-638.
- Stitt, A. W., O'neill, C. L., O'doherty, M. T., Archer, D. B., Gardiner, T. A. & Medina, R. J. 2011. Vascular stem cells and ischaemic retinopathies. *Progress in retinal and eye research*, 30, 149-166.
- Sullivan, P., Luff, A., Julious, S. & Canning, C. 1993. Patient satisfaction following vitreoretinal surgery. *Eye*, 7, 433-435.
- Tan, G. S.-W., Chakravarthy, U. & Wong, T. Y. 2020. Anti-VEGF Therapy or Vitrectomy Surgery for Vitreous Hemorrhage From Proliferative Diabetic Retinopathy. *JAMA*, 324, 2375-2377.
- Wang, W. & Lo, A. C. 2018. Diabetic retinopathy: pathophysiology and treatments. *Int. J. Mol. Sci.*, 19, 1816.
- Wirkkala, J., Bloigu, R. & Hautala, N. M. 2019. Intravitreal bevacizumab improves the clearance of vitreous haemorrhage and visual outcomes in patients with proliferative diabetic retinopathy. *BMJ open ophthalmology*, 4, e000390.
- Wu, L., Fernandez-Loaiza, P., Sauma, J., Hernandez-Bogantes, E. & Masis, M. 2013. Classification of diabetic retinopathy and diabetic macular edema. *World J. Diabetes*, 4, 290.
- Yang, C.-M., Yeh, P.-T., Yang, C.-H. & Chen, M.-S. 2008. Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy. *Am. J. Ophthalmol.*, 146, 211-217. e1.
- Zhang, T., Zhang, J., Sun, X., Tian, J., Shi, W. & Yuan, G. 2017. Early vitrectomy for dense vitreous hemorrhage in adults with non-traumatic and non-diabetic retinopathy. *Journal of International Medical Research*, 45, 2065-2071.
- Zhao, Y. & Singh, R. P. 2018. The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy. *Drugs in context*, 7.